Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-25-082904
Filing Date
2025-09-02
Accepted
2025-09-02 07:02:44
Documents
1
Period of Report
2025-08-27

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 4097
  Complete submission text file 0001213900-25-082904.txt   5798
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Issuer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address
Papapetropoulos Spyros (Reporting) CIK: 0001832694 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41157 | Film No.: 251282919